• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

    10/31/24 11:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email

    WEST BRIDGEWATER, Mass., Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ:ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expertise.

    arthrosurface company logo

    Arthrosurface: A Pioneer in Joint Restoration and Preservation

    Shane Shankle, who was appointed Arthrosurface's new President said, "As a leader in joint preservation, I'm excited to drive our company's growth plan by delivering products that help patients maintain an active quality of life."   Frank Fedorowicz, Chief Operating and Financial Officer, added, "I'm very happy to be reunited with many of our founding executives to propel Arthrosurface into its next exciting phase."

    With a commitment to minimally invasive techniques, Arthrosurface products are designed to restore natural joint function while preserving surrounding bone and tissue. Arthrosurface's product portfolio includes more than 150 different surface implant curvatures for the knee, shoulder, wrist and toe that are designed to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. Andrea Patisteas, Senior Executive Vice President emphasized that "With over two decades of clinical experience with our implants, we're thrilled to continue working with physicians and patients to provide them with options for the treatment of orthopedic conditions."  Steven Tallarida, President and CEO of Primo Medical Group simply commented "It is great to be back!"

    Phoenix Brio will be Arthrosurface's parent company, and both will be based in West Bridgewater, Massachusetts. "The acquisition of Arthrosurface aligns with our mission to create and deliver innovative medical solutions that address today's clinical needs. Arthrosurface is a natural fit for us," said Chris LaPlante, CFO at Primo Medical Group.

    Customers and distributors of Arthrosurface products should not expect to see any change in service or disruption in product access or availability.

    About Primo Medical Group

    Primo Medical Group offers the most comprehensive outsourcing solutions for the medical device market, including OEM product distribution services, engineering services, precision component production, finished goods assembly, medical device refurbishment, reusable surgical kit management and complete supply chain management. Established in 1953, Primo Medical Group is a privately held company with five facilities in Massachusetts. Primo Medical Group is an FDA Registered Contract Manufacturer and is compliant with FDA Quality Systems Regulations. Primo Medical Group is also ISO 13485:2016 certified and is a registered manufacturer with the Office of Defense Trade Controls Compliance. Over the past 24 years Primo Medical Group has incubated and co-funded several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface (acquired by Anika Therapeutics), Spirus Medical, Inc. (acquired by Olympus), Saphena Medical Inc. (acquired by a major strategic in 2024), Cardiosolutions, Inc., Trax Surgical, Inc. and Versago Vascular Access.

    For media inquiries, please contact:

    Andrea Patisteas

    781-828-4400

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/arthrosurface-returns-to-it-roots-following-divestiture-from-anika-therapeutics-302292970.html

    SOURCE Primo Medical Group

    Get the next $ANIK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recent acquisition did Primo Medical Group make?

      Primo Medical Group has acquired Arthrosurface, Inc., a provider of joint restoration solutions, from Anika Therapeutics.

    • What is the primary focus and product range of Arthrosurface?

      Arthrosurface focuses on orthopedic joint preservation solutions with a portfolio of over 150 products for treating extremity conditions.

    • What is the name of the parent company for Arthrosurface following the acquisition?

      Arthrosurface will be positioned under Phoenix Brio, which is the new parent company based in West Bridgewater, Massachusetts.

    • Will the acquisition affect existing customers and distributors of Arthrosurface?

      Customers and distributors should expect no changes in service or disruption in access to Arthrosurface products post-acquisition.

    • Who are the key executives mentioned in the acquisition announcement?

      Shane Shankle, Arthrosurface's new President, and Frank Fedorowicz, CFO, expressed excitement about resuming growth and working with founding executives.

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference

    BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a on

    2/18/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's

    2/12/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

    NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat

    2/4/26 8:54:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Griffin Stephen D.

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    2/3/26 6:45:54 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Vogt Susan L N was granted 14,164 shares, increasing direct ownership by 39% to 50,213 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:14:37 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Richard Stephen was granted 14,164 shares, increasing direct ownership by 42% to 47,871 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:13:40 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics upgraded by Barrington Research with a new price target

    Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

    8/14/23 9:16:10 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    SEC Filings

    View All

    Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

    1/8/26 4:02:04 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/7/25 6:06:11 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Anika Therapeutics Inc.

    S-8 - Anika Therapeutics, Inc. (0000898437) (Filer)

    11/5/25 4:01:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    View All

    Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

    NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat

    2/4/26 8:54:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Announces Leadership Transition

    Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griff

    1/8/26 7:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    $ANIK
    Financials

    Live finance-specific insights

    View All

    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's

    2/12/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 53754. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.a

    10/23/25 4:01:16 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

    SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/8/24 2:17:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    5/30/24 4:31:25 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/6/24 7:30:09 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care